Bilastine PCD Pharma Franchise Company

Cafoli Lifecare offers a Bilastine range of 12 formulations across tablets, syrup and suspension, manufactured in WHO-GMP certified facilities. Distributors serving dermatology, ENT and general-practice prescribers can secure district-wise monopoly franchise rights for this modern non-sedating antihistamine with full promotional support.

What is Bilastine?

Bilastine is a second-generation, non-sedating H1-antihistamine. It selectively blocks peripheral histamine H1 receptors without significant central nervous system penetration, controlling allergic symptoms with a low risk of drowsiness and no need for dose adjustment with food-independent, once-daily use. Reference: PubChem - Bilastine.

Available Forms

The Cafoli Bilastine portfolio includes oral Tablets for adults and Syrup and Suspension for paediatric and elderly patients, often combined with montelukast. Contact us for current pack presentations and combinations.

Therapeutic Applications

Bilastine is prescribed for allergic rhinoconjunctivitis (seasonal and perennial) and for urticaria and other allergic skin conditions. Prescribers include dermatologists, ENT specialists, paediatricians, chest physicians and general practitioners.

Why Bilastine is a High-Potential Molecule for Distributors

Bilastine is one of the newest non-sedating antihistamines and is rapidly gaining share from older molecules because it does not cause drowsiness, making it a preferred choice for working adults. As a newer, premium-positioned antihistamine with strong dermatologist and ENT support and year-round allergy demand, it offers distributors better margins than commoditised older antihistamines.

Why Choose Cafoli Lifecare

Cafoli Lifecare offers monopoly franchise rights, WHO-GMP certified manufacturing, DCGI-approved formulations, a network of 1000+ franchise partners across India, and free promotional inputs.

References

1. PubChem: Bilastine
2. PubMed: bilastine in rhinitis and urticaria
3. MedlinePlus: antihistamines